This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mahoney, R. T. Search for Related Content Social Bookmarking                   What's this?

Public–Private Partnership in the Development of the Hepatitis B Vaccine in Korea

Implications for Developing Countries

Richard T. Mahoney is Research Professor, School of Life Sciences, Arizona State University, 53 Gambel Lane, Sedona, AZ 86336, USA. E-mail: richard.mahoney{at}asu.edu.

National innovation in science and technology depends on many factors. This article presents a case study of the development of hepatitis B vaccine in Korea. It examines the influence of government policy, private sector strategies, intellectual property rights, regulatory frameworks, and programmes of foundations and other donors. The article leads to the conclusion that the most important factor to stimulate the development of products for developing countries is the creation of markets through, for example, the creation of international procurement funds to bridge the gap between real needs and effective demand. Intellectual property rights are often portrayed as a major deterrent to the availability of products for the poor in developing countries, but the hepatitis B case study does not support this assertion. On the national front, the most important inputs of the government are to support biomedical research, to provide transparent means of intellectual property protection and to support the development of national drug regulatory agencies.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?